About me
Dr. Andrew Chang is a multifaceted quality and CMC leader with 30 years well-rounded medical product regulatory and industry experiences. He is a member of the board of directors for Parenteral Drug Association (PDA). Andrew has served as a member of the planning committee for DIA global annual conferences from 2019 to 2023. At his current capacity as a Sr. Quality and Regulatory Director, Science, Policy and Intel., RQ&C, Novo Nordisk, he provides strategic leadership on Regulatory and Quality related Policies, External Affairs, strategic advice and solutions to quality and regulatory related challenges. Prior to industry, Andrew served more than 11 years in US FDA most recently as an Associate Director for Policy and Regulation, DH/CBER.
